Categories: News

Alimera Sciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022, and Provide Corporate Update

Conference Call to be held Thursday, February 24, 2022, at 9:00am Eastern Time

ATLANTA, Feb. 17, 2022 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report fourth quarter and full year 2021 financial results on Thursday, February 24, 2022, prior to the market open.

Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question-and-answer session.

Participants are asked to pre-register for the call.

Please note that registered participants will receive their dial-in number upon registration and will dial directly into the call without delay. Those without Internet access or who are unable to pre-register may dial in by calling 1-844-839-2190 (domestic) or 1-412-717-9583 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Alimera Sciences call.

The conference call will also be available through a live webcast, which is also available through the company’s website.

A webcast replay of the call will be available approximately one hour after the end of the call through May 24, 2022. The webcast replay can be accessed through the above links or by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code 2238986. The telephonic replay will be available until March 10, 2022.

About Alimera Sciences, Inc.
Alimera Sciences is a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer. For more information, please visit www.alimerasciences.com.

For press inquiries:
Jules Abraham
for Alimera Sciences
917-885-7378
julesa@coreir.com  
For investor inquiries:
Scott Gordon
for Alimera Sciences 
scottg@coreir.com

Staff

Recent Posts

Welldoc Partners with CLEAR to Integrate Secure Identity Verification in AI-Powered Cardiometabolic Health Platform

Collaboration Advances CMS Health Tech Ecosystem Goals by Enabling Seamless, Secure Access to Health Data…

2 hours ago

Both Ends Believing Celebrates 15 Years of Transforming Global Child Welfare Through Technology

DALLAS, Dec. 4, 2025 /PRNewswire/ -- Both Ends Believing (BEB), a Dallas-based global nonprofit with…

2 hours ago

Sage introduces skilled nursing solution to Sage Core, expanding its unified platform across all levels of senior care

Skilled brings wireless-first nurse call, real-time insights, and integrated workflows, completing Sage Core's support across…

2 hours ago

MJFF Initiates Funding for Emerging Therapeutic Targets in Parkinson’s Disease

NEW YORK, Dec. 8, 2025 /PRNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF)…

2 hours ago

Clinical Communication & Collaboration Market worth $5,302.9 million by 2030 | MarketsandMarkets™

DELRAY BEACH, Fla., Dec. 8, 2025 /PRNewswire/ -- According to MarketsandMarkets™, the Clinical Communication & Collaboration…

2 hours ago

Dr. Shawn Griffin recognized as one of Modern Healthcare’s 100 Most Influential People in Healthcare

WASHINGTON, Dec. 8, 2025 /PRNewswire/ -- URAC is proud to announce that its President and CEO,…

2 hours ago